IceCure Medical Ltd (NASDAQ:ICCM) Sees Significant Drop in Short Interest

IceCure Medical Ltd (NASDAQ:ICCM) was the recipient of a large decrease in short interest during the month of January. As of January 31st, there was short interest totalling 802,800 shares, a decrease of 9.2% from the January 15th total of 883,900 shares. Based on an average trading volume of 607,200 shares, the days-to-cover ratio is currently 1.3 days. Approximately 3.3% of the company’s stock are sold short.

Analyst Upgrades and Downgrades

A number of research firms have weighed in on ICCM. Alliance Global Partners raised IceCure Medical to a “strong-buy” rating in a research report on Friday, November 1st. HC Wainwright reaffirmed a “buy” rating and set a $2.50 price target on shares of IceCure Medical in a research report on Wednesday, November 27th.

IceCure Medical Trading Up 12.5 %

NASDAQ ICCM opened at $1.53 on Wednesday. The company has a market cap of $84.92 million, a PE ratio of -5.28 and a beta of 0.40. The company has a current ratio of 2.67, a quick ratio of 2.27 and a debt-to-equity ratio of 0.02. IceCure Medical has a 12 month low of $0.48 and a 12 month high of $1.63. The stock has a 50 day moving average of $1.20 and a 200-day moving average of $0.85.

IceCure Medical (NASDAQ:ICCM) last released its quarterly earnings data on Tuesday, November 26th. The company reported ($0.08) EPS for the quarter, missing the consensus estimate of ($0.07) by ($0.01). IceCure Medical had a negative net margin of 376.85% and a negative return on equity of 124.44%. On average, equities research analysts anticipate that IceCure Medical will post -0.28 EPS for the current fiscal year.

Institutional Investors Weigh In On IceCure Medical

An institutional investor recently raised its position in IceCure Medical stock. Geode Capital Management LLC boosted its holdings in IceCure Medical Ltd (NASDAQ:ICCM) by 58.3% during the fourth quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The firm owned 40,453 shares of the company’s stock after acquiring an additional 14,893 shares during the period. Geode Capital Management LLC owned 0.07% of IceCure Medical worth $44,000 as of its most recent filing with the Securities and Exchange Commission. Institutional investors and hedge funds own 0.62% of the company’s stock.

IceCure Medical Company Profile

IceCure Medical Ltd, a commercial stage medical device company, engages in the research, development, and marketing of cryoablation systems, disposables, and technologies for treating tumors. The company offers ProSense system, a single probe system for the treatment of tumors, as well as associated disposables; and IceSense3 system for ablation indications to urology, oncology, dermatology, gynecology, general surgery, thoracic surgery, and proctology.